The purpose of this study is to examine pharmacokinetics and dose proportionality of
sublingual tablets containing varying doses of buprenorphine and naloxone.
Phase:
Phase 1
Details
Lead Sponsor:
National Institute on Drug Abuse (NIDA)
Collaborator:
New York MDRU
Treatments:
Buprenorphine Buprenorphine, Naloxone Drug Combination Naloxone